News and insights into the #2 pharma/medtech market - China

Greg B. Scott founded ChinaBio® in 2007 to help western life science companies achieve success in China. ChinaBio® is a consulting and advisory firm based in Shanghai that has helped over 100 U.S., European and APAC companies seeking partnerships, acquisitions, novel ... more

ALL CONTRIBUTIONS

Week In Review: Hengrui Launches US Subsidiary To Bring Novel Medicines To Global Markets
Hengrui Pharma launched a new company, Luzsana Biotechnology, which is devoted to making the most advanced medications available and affordable. Meanwhile, Sichuan Kelun Pharmaceutical out-licensed global rights for a molecule candidate to Merck.
Read
Week In Review: Zhaoke Signs $130 Million Deal For Vision-Improving Eyedrops
Zhaoke Ophthalmology acquired China/Southeast Asia rights for two eyedrop candidates from Visus Therapeutics in a $130 million deal. Meanwhile, Coherus Biosciences returned the US rights to market an Innovent Avastin biosimilar.
Read
Week In Review: OrbiMed Plans To Raise $1.1 Billion For Fifth Asia Fund
One year after raising $3.5 billion for three funds in 2021, OrbiMed, the world’s largest healthcare-dedicated investor, is back with plans for $4.75 billion in new funds despite the slowdown in biopharma exits over the past year.
Read
Week In Review: I-Mab Files For Hong Kong SPAC IPO To Acquire Life Science Company
I-Mab and one of its investors, VMS, have filed for a Hong Kong IPO of a SPAC that will raise funds to acquire a life science company. Also, RVAC Medicines completed a Series B funding that brings total funds raised since inception to $140 million.
Read
Week In Review: Wuhan Binhui Raises $47 Million For Oncolytic Virus Products
Wuhan Binhui Biotech closed a $47 million Series B financing to support its R&D of oncolytic virus products. Trevena, a Philadelphia-area CNS biopharma, closed a $40 million revenue-based financing from an affiliate of R-Bridge Healthcare Fund.
Read
Week In Review: VectorBuilder Plans $500 Million Gene Therapy Delivery CDMO In Guangzhou
Deals, financings, trials and approvals in biotech in China this week.
Read

STOCKS I FOLLOW

AXN Aoxing Pharmaceutical Company, Inc.
CRPNF China Pioneer Pharma Holdings Ltd.
CYIG CHINA YCT INTL GROUP
HCM Hutchison Chi-Med
ICLR Icon PLC
MCRPF MICROPORT SCIENTIFIC
MDCO The Medicines Company
MR Mindray Medical International Limited
NBY NovaBay Pharmaceuticals, Inc.
SCLN SciClone Pharmaceuticals, Inc.
WX WuXi PharmaTech Inc.
Load More

TWEETS

PERSONAL BLOG

Latest Posts

Work Experience

Education

Publications